Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
46 hedge funds and large institutions have $34.2M invested in Regulus Therapeutics in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 10 closing their positions.
0.01% less ownership
Funds ownership: 0.43% → 0.41% (-0.01%)
8% less funds holding
Funds holding: 50 → 46 (-4)
10% less capital invested
Capital invested by funds: $38.1M → $34.2M (-$3.9M)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ascend Capital
Orinda,
California
|
+$46K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.2K |
| 3 |
Invesco
Atlanta,
Georgia
|
+$14K |
| 4 |
Goldman Sachs
New York
|
+$11.5K |
| 5 |
BAS
Brown Advisory Securities
Baltimore,
Maryland
|
+$10.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$199K |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$147K |
| 3 |
BlackRock
New York
|
-$135K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$91.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$89.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$3K | -38 | Closed |
|
|
SWP
52
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$3K | -33 | Closed |
|
|
CWM
53
Catamount Wealth Management
Westport,
Connecticut
| – | -$1K | -13 | Closed |
|
RGLS Hedge Fund Activity: Q2 2018 in Review
46 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2018, worth a combined $34.2M — down 10% from $38.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of RGLS and 6 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 6 added.
The largest buyer was Ascend Capital, adding an estimated $46K. The largest seller was BVF Inc, cutting an estimated $199K.
- 46 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2018, down from 50 in Q1 2018.
- Funds reported $34.2M of Regulus Therapeutics stock for Q2 2018, down 10% quarter-over-quarter.
- 6 funds opened new Regulus Therapeutics positions in Q2 2018 and 10 closed out, a net change of -4 holders.
- The largest Regulus Therapeutics buyer in Q2 2018 was Ascend Capital, an estimated $46K added.
- The largest Regulus Therapeutics seller in Q2 2018 was BVF Inc, an estimated $199K sold.
Based on aggregated 13F filings for Q2 2018.